Oracle Life Sciences Connect—Philadelphia

March 28, 2024

This event begins in

  •  

    Days

  • :
     

    Hours

  • :
     

    Minutes

  • :
     

    Seconds

Why attend Oracle Life Sciences Connect?

With programs specifically developed for Oracle’s regional customer communities, this multifaceted event provides compelling sessions led by Oracle customers and industry thought leaders.

Meet with your peers and gain perspective on industry trends from leading experts on artificial intelligence, cloud-based research, real-world evidence, innovative study-site selection/activation/analytics, and additional advances that are transforming and streamlining clinical and safety development.

Philadelphia Theme: The patient voice and the role of technology in advancing patient-centered drug development and commercialization

Agenda

Times shown in

Breakfast

Welcome and speaker introductions

  • Michael Fronstin

    Global Head of Client Partnerships and Commercialization, Oracle

Redefining the patient voice

Depending upon the lens you look through, the patient's voice has various meanings. Often, the patient's voice is viewed as a one-time, individual description of a particular disease experience related to a therapeutic intervention, side effect, or impact on that person's quality of life. While essential and valid to capture this perspective, the broader perspective, and trends across a patient community or even across diseases are often missed, resulting in redundancy of data and missed critical points that can impact the project and save time and money. Ms. Thornton will highlight the importance of collaborations with patient organizations and patient thought leaders to bring innovative ideas to incorporate the patient experience into healthcare, focusing correctly on the patient.

  • Susan Thornton, CEO

    Cutaneous Lymphoma Foundation

Stigmatized health conditions: missed diagnoses and poor treatment uptake

Stigmatized health conditions are often underdiagnosed and undertreated. These conditions can represent sources of shame for afflicted individuals (e.g., obesity, STDs, skin conditions, mental health conditions, etc.) and this shame may act as a barrier to diagnosis and treatment uptake. Moreover, the burden of illness for individuals with undiagnosed or untreated stigmatized conditions is substantial, highlighting an important unmet need for improving diagnosis rates and treatment uptake among individuals with stigmatized conditions. Oracle Life Sciences will share examples which quantify the size of the diagnosis and treatment uptake problem, assess the unique drivers and barriers to diagnosis and treatment uptake among those with stigmatized conditions, and guide our clients toward better and more targeted solutions for improving diagnosis rates, treatment uptake, and subsequent health outcomes in these stigmatized populations.

  • Nate A. Way, PhD

    Senior Evidence Generation Lead for RWE, Oracle

Refreshments and networking

Voices to trials: Design for success by engaging patients in clinical trial design

Clinical trial protocols often focus on the clinical objectives of the trial and can miss key design elements that can motivate or discourage patient participation and retention. Voices to Trials is a structured approach to incorporating patient voices to optimize clinical trial design. This approach can include optimizing trial endpoints, where input, captured via interview or stated preference methodologies, can help confirm which outcomes matter most and their relative importance. We will share case studies resulting in regulatory acceptance thus accelerating enrollment, ensuring retention and success.

  • Emily Mulvihill, MBA

    Associate Principal Real World Data & Analytics, Oracle

  • Kathleen Beusterien, MPH

    Principal of RWE, Oracle

Community Engagement to Increase Diversity in Clinical Trials

In a discussion with clinicians focused on community engagement, we will start with an updated exploration of the challenges and barriers to recruiting and enrolling diverse populations in clinical trials. They will then illustrate the strategies and resources needed to connect diverse communities to research by sharing their work, successes, and evidence towards overcoming these barriers. Finally, we will consider the potential for AI in supporting equity in clinical trial participation.

  • Emily Mulvihill, MBA

    Associate Principal Real World Data & Analytics, Oracle

  • Dr. Carmen E. Guerra, M.D., M.S.C.E., F.A.C.P.

    Professor of Medicine, University of Pennsylvania

  • Dr. Mylynda Massart, MD, Ph.D.

    Associate Professor, University of Pittsburgh

Lunch

Patient registries in the era of electronic health record big data

Patients’ registries are increasingly moving away from data collection that is duplicative to the care process to unified and EHR-integrated workflows whereby data can be collected once to be used for many purposes. In addition, there is a push for modernization of data dictionary models and workflow tools by leveraging new interoperability standards and adding emerging technology components that simplify, automate, and amplify Real World Data acquisition. Our vision for the future of registries focuses on the development of a single system able to extract validated, high-quality EHR data, collect primary data from clinicians and patients and ingest and link to other data sources. This system should enable us to collect data on patients regardless of where they are treated while reducing the data collection burdens on clinicians, researchers, patients and information technology staff alike.

  • Tonya Hongsermeier, MD, MBA

    VP Chief Clinical Innovation Officer, Elimu

  • Elise Berliner, PhD

    Global Senior Principal RWE Strategy, Oracle

Applications of machine learning to score freezing of gait in people with Parkinson's disease

There is a need for valid and reliable outcome measures for clinical trials in Parkinson's disease (PD) and other conditions. Freezing of gait (FOG) is a poorly understood heterogeneous gait disorder seen in these patients that contributes to significant morbidity and social isolation. FOG is currently measured subjectively by movement disorders specialists or through patient completed questionnaires (N-FOG-Q) that are unsuitable for use in clinical trials. Methods to quantitatively assess FOG through machine learning could potentially significantly improve precision of clinical trials as well as access to care. Drs. Kwon and McKay will present a recent study from their laboratory that applied state-of-the-art deep learning approaches to score FOG in people with PD.

  • Lysel Brignoli (Moderator)

    Associate Principal, RWE, Oracle

  • Dr. Hyeokhyen Kwon, Ph.D., M.Sc

    Assistant Professor, Department of Biomedical informatics, School of Medicine, Emory University

  • Dr. J. Lucas Mckay, Ph.D., M.S.C.R.

    Assistant Professor, Department of Biomedical informatics, School of Medicine, Emory University

Refreshments and networking

Advancing patient-centered drug development and clinical trials with AI-powered cloud infrastructure

The convergence of science and emerging technologies, such as AI and machine learning, is enabling patient-centric approaches to clinical trials with data-driven insights to optimize study design, predict patient responses, improve patient adherence and retention, and to foster inclusiveness and diversity. Capturing the patient voice through the collection of real-world data (e.g., EHRs, claims, disease registries, digital health apps, social media) is an integral part of this approach and critical for efficient post-marketing studies. AI-enabled applications and algorithms are also impacting the full lifecycle of therapeutic development, from discovery to commercialization, with the power to find patterns lost by conventional data analysis. Learn how Oracle is helping life science organizations unify data and analytics across the enterprise to unlock the full potential of their mission critical data through our Life Sciences applications, Oracle Cloud Infrastructure, and data & analytics services.

  • Dr. Bryan Barker, Ph.D.

    AI Cloud Senior Specialist, Healthcare and Life Sciences, Oracle

Transforming Clinical Trials through Embedded AI, Purified Real World Data, and Causal Inference

In the rapidly evolving landscape of clinical trials, the convergence of three critical elements—Artificial Intelligence derived from and delivered into clinical delivery, purified real-world data, and the application of causal inference—presents a transformative opportunity to reshape the field. The most impactful AI will minimize risks by creating a safe, transparent, equitable, effective, and secure AI system and maximize benefit by being integrated with clinical workflow. At the core of harnessing the full potential of AI lies the purification of real-world data (RWD). This includes the automatic ingestion and transformation of heterogeneous clinical data, encompassing both structured and unstructured formats, into a unified, high-quality dataset characterized by interoperability, normalization, and integrity. Moreover, at Ronin, we have shown that Doubly Robust Causal Machine Learning methods can bring statistical precision to observational RWD such as that from electronic medical records, comparable to randomized controlled trials. This approach not only facilitates personalized patient care but can also optimize clinical trial designs, improve safety, and reduce dropout, leading to more efficient trials, lower costs, and increased success rates.

  • Christine Swisher, PhD

    Chief Scientific Officer, Ronin Ellison Institute of Technology Coalition of Health AI

Refreshments and networking

Big data and AI has finally come to commercialization in life science

We are now realizing the promise of healthcare expertise and quality data streams because we are bringing to bear the full force of Oracle real world data and technology. Our new approach to life sciences questions rooted in observed patient data will drive better decision making and enable broad improvements in patient health. Dani Niblick and Marie Giordano will discuss how we are harnessing healthcare expertise and data sources, including real world anonymized patient data to redefine the depth and speed of understanding available to improve decision making during the commercialization process.

  • Dani Niblick

    Principal of Advanced Analytics, Oracle

  • Marie Giordano

    Business Leader of US Commercial Research, Oracle

Closing speech

  • David Fantini

    Vice President of Sales, North America, Oracle

Networking reception

End the day by joining Oracle for a fun filled networking reception with cocktails, conversations, and canapés!'

Welcome, we're your hosts

Lysel Brignoli headshot
Lysel Brignoli Associate principal, RWE
Elise Berliner headshot
Elise Berliner Global senior principal of real world evidence strategy
    Event location
    Oracle Malvern
    51 Valley Stream Parkway
    Malvern, PA 19355
  • +1.610.219.6300
  • Driving directions

Explore Oracle Life Sciences solutions and resources.